The stock will trade on upcoming clinical catalysts: PBGENE-HBV late-breaker data at EASL (May 27-30) and PBGENE-DMD enrollment updates. Cash runway through 2028 removes near-term financing overhang. Monitor for any safety signals or efficacy readouts from the EASL poster.
Price Chart
Executive Summary
Precision BioSciences reported Q1 2026 revenue of $10.8M (up from ~$0.1M YoY) and a net loss of $(0.75)/share, narrowing from $(2.21)/share in Q1 2025. The quarter was driven by milestone revenue from TG Therapeutics and a legacy collaboration, while clinical execution advanced for PBGENE-HBV (16 patients dosed, late-breaker at EASL) and PBGENE-DMD (first site activated, enrolling patients). Cash of $125.8M is expected to fund both programs through 2028.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $10.8M vs ~$0.1M in Q1 2025, driven by TG Therapeutics milestone and legacy collaboration
- Net loss narrowed to $(18.4M) or $(0.75)/share from $(20.6M) or $(2.21)/share YoY
- Cash, cash equivalents, and restricted cash of $125.8M as of March 31, 2026
- PBGENE-HBV: 16 patients dosed across 5 cohorts; late-breaking poster accepted at EASL Congress May 27-30
- PBGENE-DMD: First clinical site (Arkansas Children's Hospital) activated and enrolling patients in FUNCTION-DMD trial
- TG Therapeutics milestone payment of $7.5M received in April 2026 ($5.25M cash + $2.25M stock)
- Cash runway expected through 2028, sufficient for PBGENE-HBV and PBGENE-DMD data milestones
Financial Impact
Revenue of $10.8M (up from ~$0.1M YoY) driven by milestone payments; net loss improved to $(18.4M) from $(20.6M) YoY
Risk Factors
- PBGENE-HBV Phase 1 data at EASL may show safety or efficacy concerns
- PBGENE-DMD enrollment could face delays at specialized clinical sites
- Reliance on milestone revenue from partners (TG Therapeutics, Imugene) is non-recurring
- Operating loss of $(9.1M) in Q1 2026 still significant for a $197M market cap company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-030123 |
| Document: dtil-20260505.htm | 0001628280-26-030123 |
| Document: 0001628280-26-030123-index-headers.html | 0001628280-26-030123 |
| Document: 0001628280-26-030123-index.html | 0001628280-26-030123 |
| Document: 0001628280-26-030123.txt | 0001628280-26-030123 |
| 8-K Data (Synthetic) | 0001628280-26-030123 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $6.39 | awaiting T+1 | — | $6.79 (+6.26%) |
Sep 22, 2026 5w ago | Institutional Cluster | $7.19 $6.36 | ▼ −11.54% | ▼ −10.82% | $6.79 (−5.56%) |
Aug 24, 2026 9w ago | 8-K | $8.45 $8.55 | ▲ +1.18% | ▲ +0.86% | $6.79 (−19.64%) |
Aug 6, 2026 11w ago | 8-K | $7.42 $7.49 | ▲ +0.94% | ▲ +0.33% | $6.79 (−8.49%) |
Jul 27, 2026 13w ago | 8-K | $7.25 $7.17 | ▼ −1.10% | ▼ −1.34% | $6.79 (−6.34%) |
Jul 1, 2026 16w ago | 8-K | $7.88 $8.18 | ▲ +3.81% | ▲ +3.94% | $6.79 (−13.83%) |
Jun 16, 2026 19w ago | 8-K | $6.50 $6.81 | ▲ +4.77% | ▲ +3.99% | $6.79 (+4.46%) |
May 27, 2026 21w ago | 8-K | $7.59 $6.92 | ▼ −8.83% | ▼ −9.38% | $6.79 (−10.54%) |
May 26, 2026 22w ago | 8-K | $7.59 $6.92 | ▼ −8.83% | ▼ −9.38% | $6.79 (−10.54%) |
May 5, 2026 25w ago | 8-K | $7.45 $7.52 | ▲ +0.94% | ▼ −0.45% | $6.79 (−8.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers